This special edition episode is brought to you by the AmerisourceBergen Insights podcast. In Part 1 of this two-part series on insulin biosimilars, host Jennifer Kemper, Director of Content Strategy, speaks with Sean McGowan, Senior Director of Biosimilars, Michelle Jesse, Director of Biosimilar Commercialization, and Brad Tallamy, Senior Director of Government Affairs, about what these new drugs could mean for the category. They’ll discuss how and why insulins are in the biosimilar category, how congress is approaching biosimilars, and if an interchangeability status is on the horizon.